Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0037315 (
sleep apnea
)
8,000
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A 60-year-old woman with acromegaly associated with
sleep apnea
was treated with the somatostatin analogue
SMS
201-995 (Sandoz) for several months. Growth hormone levels were normalized and a rapid improvement in
sleep apnea
was controlled with polygraphic nocturnal monitoring. Hypophysectomy seems to have variable effects on
sleep apnea
in acromegaly. The origin of obstructive apnea in acromegaly is therefore unclear.
...
PMID:[Long-term effects of treatment with SMS 201-995 on sleep apnea syndrome associated with acromegaly]. 261 48
Potocki-Lupski syndrome (PTLS; MIM 610883) is a neurodevelopmental disorder caused by a microduplication, a 3.7 Mb copy number variant, mapping within chromosome 17p11.2, encompassing the dosage-sensitive RAI1 gene. Whereas RAI1 triplosensitivity causes PTLS, haploinsufficiency of RAI1 due to 17p11.2 microdeletion causes the clinically distinct Smith-Magenis syndrome (
SMS
; MIM 182290). Most individuals with
SMS
have an inversion of the melatonin cycle. Subjects with PTLS have mild sleep disturbances such as
sleep apnea
with no melatonin abnormalities described. Sleep patterns and potential disturbances in subjects with PTLS have not been objectively characterized. We delineated sleep characteristics in 23 subjects with PTLS who underwent a polysomnogram at Texas Children's Hospital. Eleven of these subjects (58%) completed the Child's Sleep Habits Questionnaire (CSHQ). Urinary melatonin was measured in one patient and published previously. While the circadian rhythm of melatonin in PTLS appears not to be disrupted, we identified significant differences in sleep efficiency, percentage of rapid eye movement sleep, oxygen nadir, obstructive apnea hypopnea index, and periodic limb movements between prepubertal subjects with PTLS and previously published normative data. Data from the CSHQ indicate that 64% (7/11) of parents do not identify a sleep disturbance in their children. Our data indicate that younger individuals, <10 years, with PTLS have statistically significant abnormalities in five components of sleep despite lack of recognition of substantial sleep disturbances by parents. Our data support the contention that patients with PTLS should undergo clinical evaluations for
sleep disordered breathing
and periodic limb movement disorder, both of which are treatable conditions.
...
PMID:Objective measures of sleep disturbances in children with Potocki-Lupski syndrome. 3134 17